232 related articles for article (PubMed ID: 29574790)
21. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
Nakagawa M; Kitabayashi I
Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
24. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans.
Yang F; Zhang L; Huo XS; Yuan JH; Xu D; Yuan SX; Zhu N; Zhou WP; Yang GS; Wang YZ; Shang JL; Gao CF; Zhang FR; Wang F; Sun SH
Hepatology; 2011 Nov; 54(5):1679-89. PubMed ID: 21769904
[TBL] [Abstract][Full Text] [Related]
26. Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Deng X; Zhao XF; Liang XQ; Chen R; Pan YF; Liang J
Biomed Pharmacother; 2017 Jun; 90():100-108. PubMed ID: 28343069
[TBL] [Abstract][Full Text] [Related]
27. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
[TBL] [Abstract][Full Text] [Related]
28. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
29. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
[TBL] [Abstract][Full Text] [Related]
30. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
[TBL] [Abstract][Full Text] [Related]
31. Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma.
Kgatle MM; Setshedi M; Hairwadzi HN
Biomed Res Int; 2016; 2016():3956485. PubMed ID: 28105421
[TBL] [Abstract][Full Text] [Related]
32. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma.
Tu T; Budzinska MA; Shackel NA; Jilbert AR
Liver Int; 2015 Jul; 35(7):1786-800. PubMed ID: 25640596
[TBL] [Abstract][Full Text] [Related]
33. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
Chen Y; Lin MC; Yao H; Wang H; Zhang AQ; Yu J; Hui CK; Lau GK; He ML; Sung J; Kung HF
Hepatology; 2007 Jul; 46(1):200-8. PubMed ID: 17596871
[TBL] [Abstract][Full Text] [Related]
34. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
[TBL] [Abstract][Full Text] [Related]
36. Integrin α6 as an invasiveness marker for hepatitis B viral X-driven hepatocellular carcinoma.
Kim YR; Byun MR; Choi JW
Cancer Biomark; 2018; 23(1):135-144. PubMed ID: 30010110
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis.
Rongrui L; Na H; Zongfang L; Fanpu J; Shiwen J
Curr Pharm Des; 2014; 20(11):1715-25. PubMed ID: 23888939
[TBL] [Abstract][Full Text] [Related]
38. HBx-upregulated lncRNA UCA1 promotes cell growth and tumorigenesis by recruiting EZH2 and repressing p27Kip1/CDK2 signaling.
Hu JJ; Song W; Zhang SD; Shen XH; Qiu XM; Wu HZ; Gong PH; Lu S; Zhao ZJ; He ML; Fan H
Sci Rep; 2016 Mar; 6():23521. PubMed ID: 27009634
[TBL] [Abstract][Full Text] [Related]
39. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
Huang B; Huang M; Li Q
Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
[TBL] [Abstract][Full Text] [Related]
40. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
